Trade Revance Therapeutics Inc - RVNC CFD

Revance The Company profile

About Revance Therapeutics Inc

Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Revance Therapeutics Inc revenues increased from $15.3M to $77.8M. Net loss increased less than 1% to $281.3M. Revenues reflect Product Segment increase from $14.9M to $76.5M, Service Segment increase from $417K to $1.3M. Net loss reflects Research & Development balance decrease of 11% to $99.4M (expense), Interest expense decrease of 59% to $6.3M (expense).